Autopsy report · NCT03384836

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

“interim Analysis”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Suspended: paused, and may or may not restart.
• 47 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1, Phase 2

Sponsor

Roswell Park Cancer Institute

Sponsor type

University, hospital or other

Conditions

Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

Laboratory Biomarker Analysis; Pembrolizumab; Propranolol Hydrochloride

Participants

47 (planned, not actual)

Sites

4

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.